hypoglycemia

stock image of a glucose meter with a blood strip
Biotech

Rezolute stock sinks 87% as hypoglycemia drug fails ph. 3 test

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application.
James Waldron Dec 11, 2025 9:45am
Photo of a train heading toward the Eiger mountain peaks

Eiger descends from COVID peak after pivoting, cuts 25% of staff

Jun 29, 2023 9:52am